| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiviral, monoclonal antibodies | 5683 | 2420564-02-7 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Tixagevimab is a recombinant human IgG1 monoclonal antibody used in combination with cilgavimab for the treatment of COVID-19.
|
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 25, 2022 | EMA | AstraZeneca AB | |
| Aug. 30, 2022 | PMDA | AstraZeneca K.K. |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic epidermal necrolysis | 45.60 | 35.88 | 7 | 3 | 21639 | 34935282 |
None
None
| Source | Code | Description |
|---|---|---|
| ATC | J06BD03 | ANTIINFECTIVES FOR SYSTEMIC USE IMMUNE SERA AND IMMUNOGLOBULINS IMMUNOGLOBULINS Antiviral monoclonal antibodies |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| COVID-19 | indication | 840539006 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Spike glycoprotein | Glycoprotein | BINDING AGENT | Kd | 11.56 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| CHEMBL4650265 | ChEMBL_ID |
| C000714167 | MESH_SUPPLEMENTAL_RECORD_UI |
| C000714187 | MESH_SUPPLEMENTAL_RECORD_UI |
| C000714168 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11330 | IUPHAR_LIGAND_ID |
| DB16394 | DRUGBANK_ID |
| 018902 | NDDF |
| 4041036 | VANDF |
| C5432264 | UMLSCUI |
| 11776 | INN_ID |
| D11993 | KEGG_DRUG |
| 2587300 | RXNORM |
| 353927 | MMSL |
| 40135 | MMSL |
| d09834 | MMSL |
| F0LZ415Z3B | UNII |
None